New CAR T therapy targets solid tumours safely and effectively
USC researchers have engineered CAR T cells to deliver a dual protein therapy that targets solid tumours – offering hope for cancers previously resistant to treatment.
List view / Grid view
USC researchers have engineered CAR T cells to deliver a dual protein therapy that targets solid tumours – offering hope for cancers previously resistant to treatment.
A new dual CAR-T cell therapy targeting two tumour-specific proteins in T-cell Acute Lymphoblastic Leukaemia (T-ALL) has been developed – meaning effective treatment for this aggressive blood cancer could soon become a reality.
A new “leukaemia-on-a-chip” device replicates human bone marrow and immune interactions, enabling researchers to observe CAR T cell therapies in action - potentially allowing for more personalised treatment strategies for leukaemia patients.